A Food and Drug Administration advisory panel on Monday endorsed the experimental Alzheimer's drug donanemab, which studies showed slowed early stages of the fatal mind-robbing disease.
The recommendation came despite pointed questions from advisory committee members about the potential side effects of Eli Lilly's drug, an antibody that removes beta-amyloid that accumulates in the brains of patients with Alzheimer's disease.
The FDA is not compelled to follow the recommendation of the advisory committee of outside experts, but it often does so. A notable exception was when the advisory committee recommended the agency reject Biogen's amyloid-clearing drug aducanumab, nevertheless, the FDA in 2021 approved the drug. Biogen halted sales and gave up ownership of the drug earlier this year.
JD Vance, the Ohio senator and Donald Trump’s running mate, promoted a baseless rightwing talking point...
The Nebraska Supreme Court denied a challenge to the state’s abortion restrictions and gender-affirming care in...
